Current Status of Theranos
Theranos is no longer an active health technology company. The firm was shut down after regulatory and legal actions, and its former CEO Elizabeth Holmes is serving a prison sentence. The company's blood-testing technology was found to be fraudulent, and its consumer product was never approved for medical use. Theranos does not operate clinics or sell devices today. Forbes reported the conviction and the end of the company's operations.
Holmes was sentenced in November 2022 to 11 years and 3 months in federal prison for fraud. She is currently incarcerated at Federal Prison Camp, Bryan in Texas. Theranos' former president Sunny Balwani was convicted on all 12 counts and sentenced to 12 years and 11 months. The company's assets were liquidated, and its former laboratory in Newark, California was permanently closed. No Theranos-branded products or services remain available to consumers or investors.
Legal and Regulatory Outcome
The U.S. Securities and Exchange Commission charged Holmes and Balwani with massive fraud, resulting in permanent bans from serving as officers or directors of public companies. Holmes agreed to a settlement that included forfeiture of Theranos voting control and a ten-year ban from holding leadership roles at public companies. The SEC case focused on false claims about Theranos' technology and partnerships with major companies. The SEC's official complaint details the fraud charges and final orders.
Federal prosecutors brought criminal wire fraud and conspiracy charges against both Holmes and Balwani. The jury trial in San Jose concluded with guilty verdicts on four counts against Holmes and all counts against Balwani. Prosecutors said the defendants raised more than 700 million dollars from investors while lying about the capabilities of their blood-testing platform. Theranos' former laboratory operations were also subject to enforcement actions by the Centers for Medicare and Medicaid Services, which revoked its certification.
What Replaced Theranos in the Market
After Theranos collapsed, investors and partners shifted to established diagnostic and health technology companies. Companies such as Abbott, Roche, and Siemens Healthineers continue to dominate the blood-testing and diagnostics market. Modern point-of-care testing devices from these firms use well-validated technology and regulatory clearances. Forbes covered how the market moved on from Theranos to trusted medical device makers.
Holmes and Balwani are prohibited from starting new health technology companies in the U.S. while under their regulatory bans. The Theranos case became a reference point for due diligence in health tech investing. Venture capital and corporate partners now require stricter validation of medical claims and regulatory approvals. The collapse of Theranos is cited in industry analyses as a cautionary example of unverified health technology claims.